What do TSECs provide in the menopausal hormone therapy?

Abstract

Tissue-selective estrogen complex (TSEC) is projected as a progestogen-free option for the treatment of estrogen deficiency symptoms in postmenopausal, non-hysterectomized women. TSEC combines the benefits of estrogen with a selective estrogen receptor modulator (SERM), in this case bazedoxifene acetate (BZA), which has an antagonistic effect on the endometrium, thus avoiding the use of progestins. The authorized TSEC combination (conjugated estrogens [CE] 0.45 mg/BZA 20 mg) for the alleviation of vasomotor symptoms has been demonstrated in randomized clinical trials compared with placebo or menopausal hormone therapy (MHT). In addition, TSEC has shown improvements in quality of life and vaginal atrophy. In respect to MHT using progestins, the benefits of TSEC are found mainly in the bleeding pattern, amenorrhea rate, and reduction in mammary repercussion (i.e., breast tenderness and radiological density). The objective of this guide will be to analyze the efficacy and safety of TSEC consisting of CE/BZA in postmenopausal women.

Chinese abstract

组织选择性雌激素复合物（TSEC）被认为是绝经后未行子宫切除女性治疗雌激素缺乏症的不含孕激素的药物选择。TSEC结合了雌激素和选择性雌激素受体调节剂（SERM）的优势, 醋酸巴泽多昔芬（BZA）因具有子宫内膜拮抗作用而可避免孕激素的使用。与安慰剂或绝经激素治疗（MHT）相比, TSEC复合物（结合雌激素[CE] 0.45mg/BZA 20mg）已被随机临床试验证实可用于缓解血管舒缩症状。此外, TSEC已显示出对生活质量和阴道萎缩的改善。与应用孕激素的MHT相比, TSEC的优势主要在出血模式、闭经率和乳房反应减少（即乳房触痛和放射密度）等方面。本研究的目的是分析CEEC/BZA组成的TSEC在绝经后女性中的有效性和安全性。

Keywords:

• Tissue-selective estrogen complex
• postmenopausal women
• menopausal hormone therapy

Acknowledgements

This article was translated and edited by American Journal Experts.

Disclosure statement

No potential conflict of interest was reported by the authors.

No one is on speaker’s bureaus, received research funding or consulting.

Additional information

Funding

There was no funding source for this review, and no editorial assistance was received from the company that manufactures TSEC.